tbuckley/cabot-search huggingface dataset:
IMMU-65. Lin-CCR2+ HEMATOPOIETIC STEM CELLS OVERCOME RESISTANCE TO PD-1 BLOCKADE
Authors: Catherine Flores, Tyler Wildes, Jeffrey Drake, Rebecca Abraham, Duane Mitchell
Journal: Neuro-Oncology (2017)

Harnessing the immune system for the treatment of refractory cancers through immunotherapeutic approaches has emerged as a remarkably effective treatment modality, leading to objective clinical responses in patients with advanced malignancies. Unfortunately, the majority of patients with solid tumors demonstrate resistance to immune checkpoint blockade and adoptive cellular therapy. Here we identify a subpopulation of hematopoietic progenitor cells (HSC) that express chemokine receptor type 2 (CCR2) that mount the capacity to overcome treatment resistance to immunotherapy when used in combinatorial approaches against malignant brain tumors. For immune checkpoint blockade experiments, we chose to use murine models of glioma (KR158B) and medulloblastoma (Ptc) that are refractory to monotherapy with anti-PD-1. Intracranial tumor bearing mice were treated with either anti-PD-1 alone, HSCs alone, or combination HSC + anti-PD-1. For adoptive cell therapy experiments, intracranial tumor bearing mice received adoptive cell therapy of tumor-specific T cells with or without HSC transfer. CCR2+ subset of HSCs were isolated using magnetic bead isolation for use in these experiments. We demonstrate that CCR2+HSCs in combination with PD-1 checkpoint blockade leads to significantly increased overall survival in both murine models of glioma and medulloblastoma that are refractory to PD-1 blockade alone. Co-transfer of CCR2+HSC with PD-1 led to increased T cell activation within the brain tumor microenvironment. These studies also demonstrate that in combination with adoptive T cell therapy, CCR2+HSCs lead to increased anti-tumor T-cell activation within tumor microenvironment leading to subsequent survival benefit. Together our data show a role for CCR2+HSCs in overcoming treatment resistance to immunotherapy. Of note, these cells downregulate CCR2 expression in the brain tumor microenvironment and do not differentiate into MDSCs. We demonstrate that a subset of hematopoietic stem cells overcome treatment resistance when used with either PD-1 blockade or adoptive T cell therapy in brain tumor models.
Scalp cooling: a real opportunity to prevent alopecia in breast cancer women undergoing chemotherapy?
Authors: L.R. Martella, F. Daniel, A. Moretti, I. Toma, F. Lancia, E. Tiberi, E. Mauro, A. Schirone, A. Santini, A. Frassoldati
Journal: Annals of Oncology (2017)
Vigilância Europeia da legionelose associada às viagens, em 1996
Authors: C. R. Lane, C Joseph, C L R Bartlett
Journal: Eurosurveillance (1998)

O Programa Europeu de Vigilância da Legionelose Associada as Viagens foi criado em 1987 para identificar os agrupamentos de casos e os surtos da doenca (1). Vinte e nove centros de colaboracao em 25 paises contribuem para a notificacao de casos num modelo normalizado. O programa recebeu o apoio da Organizacao Mundial de Saude (OMS) e tem sido subsidiado pela Comissao Europeia (CE) e Direccao Geral V(DGV), desde 1993. Tem sido coordenado pelo Public Health Laboratory Service (PHLS) Communicable Disease Surveillance Centre (CDSC) em Londres.
Brote de intoxicación alimentaria con Salmonella enteritidis por consumo de queso de fabricación industrial
Authors: M. G. Panico, F Primiano, F Nappi, F Attena
Journal: Eurosurveillance (1999)

Entre el 30 de junio y el 2 de julio de 1998, tres hospitales declararon nueve casos sospechosos de intoxicacion alimentaria al Servicio de Epidemiologia y Prevencion (Servizio di Epidemiologia e Prevenzione - SEP-) de la autoridad sanitaria local del distrito de Napoles (Azienda Sanitaria Locale, ASL NA 4). El SEP comenzo a investigar de inmediato el brote.
P2.17-004 Salvage Surgery for Pulmonary Metastases in Patients with Testicular Germ Cell Tumors
Authors: S. Kikuchi, Y. Sekine, K. Sugai, T. Kawamura, S. Ueda, Y. Saeki, N. Kobayashi, Y. Goto, Y. Minami, M. Onizuka, T. Kojima, K. Kawai, H. Nishiyama, H. Ichimura, Y. Sato
Journal: Journal of Thoracic Oncology (2017)
Safety and efficacy of non-pegylated liposomal doxorubicin (NPLD) in HER2 negative metastatic breast cancer (mBC) patients (PTS) as second-line (2L) and beyond: a restrospective single institution analysis
Authors: C. De Angelis, L. Diodati, I. Bertolini, I. Montagnani, A. Fontana, I. Ferrarini, B. Salvadori, P. Ferrari, A. Michelotti, E. Landucci, A. Falcone
Journal: Annals of Oncology (2017)
TMIC-26. IMMUNOMODULATION WITH TEMOZOLOMIDE TO IMPROVE EFFICACY OF IMMUNE CHECKPOINT INHIBITION FOR THE TREATMENT OF GLIOBLASTOMA
Authors: Aida Karachi, Farhad Dastmalchi, Changlin Yang, Jianping Huang, Duane Mitchell, Maryam Rahman
Journal: Neuro-Oncology (2017)

Immune checkpoint inhibitors are under active investigation as novel strategies for the treatment of newly diagnosed glioblastoma (GBM). Due to the effects of temozolomide (TMZ) on host immunity, we hypothesize that dose and timing of TMZ will impact efficacy of immune checkpoint inhibition with PD-1 blockade. C57BL/6 tumor (GL-261) bearing mice were treated with standard (50 mg/kg for 5 days) and metronomic dose (25 mg/kg for 10 days) of TMZ alone and in combination with PD-1 blockade and different cell populations and their activation/exhaustion markers were evaluated in a time dependent manner. Antigen specific T cell populations were tested for expansion and functionality. Survival was compared between groups. Both standard and metronomic TMZ induced similar levels of lymphopenia and increase Treg frequency in tumor bearing mice blood. An increase was observed in periphery myeloid derived suppressor cells (MDSCs) of tumor bearing mice treated with standard dose TMZ that was not seen in metronomic TMZ treated mice. Standard TMZ increased markers of T cell exhaustion not seen with metronomic TMZ treatment. Standard TMZ resulted in less functional antigen specific T cells in vivo. Survival analysis demonstrated standard dose TMZ decreased survival benefit achieved with PD-1 blockade, as opposed to metronomic dose TMZ which resulted in increased survival when combined with PD-1 blockade. Standard TMZ results in decreased survival of a murine glioma model when combined with PD-1 blockade due to T cell exhaustion and an increased in immunosuppressive MDSCs. Metronomic dosing of TMZ does not result in T cell exhaustion and preserves efficacy of PD-1 blockade.
Comparisons of Interventions for Preventing Falls in Older Adults
Authors: Andrea C. Tricco, Sonia M. Thomas, Areti Angeliki Veroniki, Jemila S. Hamid, Elise Cogo, Lisa Strifler, Paul A. Khan, Reid Robson, Kathryn M. Sibley, Heather MacDonald, John J. Riva, Kednapa Thavorn, Charlotte Wilson, Jayna Holroyd-Leduc, Gillian D. Kerr, Fabio Feldman, Sumit R. Majumdar, Susan B. Jaglal, Wing Hui, Sharon E. Straus
Journal: JAMA (2017)

<h3>Importance</h3> Falls result in substantial burden for patients and health care systems, and given the aging of the population worldwide, the incidence of falls continues to rise. <h3>Objective</h3> To assess the potential effectiveness of interventions for preventing falls. <h3>Data Sources</h3> MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Ageline databases from inception until April 2017. Reference lists of included studies were scanned. <h3>Study Selection</h3> Randomized clinical trials (RCTs) of fall-prevention interventions for participants aged 65 years and older. <h3>Data Extraction and Synthesis</h3> Pairs of reviewers independently screened the studies, abstracted data, and appraised risk of bias. Pairwise meta-analysis and network meta-analysis were conducted. <h3>Main Outcomes and Measures</h3> Injurious falls and fall-related hospitalizations. <h3>Results</h3> A total of 283 RCTs (159 910 participants; mean age, 78.1 years; 74% women) were included after screening of 10 650 titles and abstracts and 1210 full-text articles. Network meta-analysis (including 54 RCTs, 41 596 participants, 39 interventions plus usual care) suggested that the following interventions, when compared with usual care, were associated with reductions in injurious falls: exercise (odds ratio [OR], 0.51 [95% CI, 0.33 to 0.79]; absolute risk difference [ARD], −0.12 [95% CI, −0.20 to −0.05]); combined exercise and vision assessment and treatment (OR, 0.17 [95% CI, 0.07 to 0.38]; ARD, −0.38 [95% CI, −0.53 to −0.22]); combined exercise, vision assessment and treatment, and environmental assessment and modification (OR, 0.30 [95% CI, 0.13 to 0.70]; ARD, −0.23 [95% CI, −0.39 to −0.08]); and combined clinic-level quality improvement strategies (eg, case management), multifactorial assessment and treatment (eg, comprehensive geriatric assessment), calcium supplementation, and vitamin D supplementation (OR, 0.12 [95% CI, 0.03 to 0.55]; ARD, −0.17 [95% CI, −0.33 to 0.00]). Pairwise meta-analyses for fall-related hospitalizations (2 RCTs; 516 participants) showed no significant association between combined clinic- and patient-level quality improvement strategies and multifactorial assessment and treatment relative to usual care (OR, 0.78 [95% CI, 0.33 to 1.81]). <h3>Conclusions and Relevance</h3> Exercise alone and various combinations of interventions were associated with lower risk of injurious falls compared with usual care. Choice of fall-prevention intervention may depend on patient and caregiver values and preferences.
NIMG-48. MR IMAGING PHENOTYPE CORRELATES WITH EXTENT OF GENOME-WIDE COPY NUMBER ABUNDANCE IN IDH MUTATED GLIOMAS
Authors: Chih-Chun Wu, Rajan Jain, Seema Patel, Lucidio Neto, David Zagzag, Dimitris Placantonakis, John Golfinos, Andrew S Chi, Matija Snuderl
Journal: Neuro-Oncology (2017)

There is variability in survival within IDH-mutated gliomas determined by chromosomal events and it has been reported that copy number variation (CNV) abundance is associated with survival in low-grade glioma. The purpose of this study was to correlate the extent of genome-wide CNV in IDH-mutated gliomas with specific MR imaging features. A total of 22 cases of IDH-mutated 1p/19q non-codeleted glioma (WHO grade II-IV) with pre-operative MRI were included. We reviewed CNV plots obtained with Illumina 850k EPIC DNA methylation arrays from these tumors. Gliomas divided into two groups based on the degree of genome-wide CNV abundance into CNV stable (CNV-S) with <3 chromosomal gains or losses and lack of focal gene amplifications and CNV unstable (CNV-U) with >3 large chromosomal gains/losses and/or focal amplifications. MR morphological features including tumor location, enhancing pattern, tumor margin, presence of necrosis and cysts and size were reviewed by two neuroradiologists. Tumor blood volume estimates (rCBV) were obtained using DSC T2* perfusion analysis. Imaging features were compared by ÷2 and t-test. There were 16 (72.7%) CNV-U and 6 (27.3%) CNV-S IDH-mutated gliomas. Necrosis was significantly more prevalent in CNV-U (5/6, 83.3%) than in CNV-S IDH-mutated gliomas (2/16, 12.5%; p = 0.004). Mean tumor size based on FLAIR was significantly smaller in CNV-S (23.2 ± 3.6mm) than in CNV-U IDH-mutated gliomas (42.6 ± 6.2mm, p = 0.013). CNV-S IDH-mutated gliomas demonstrated significantly lower mean rCBV (1.4 ± 0.4) than CNV-U gliomas (4.0 ± 1.1, p =0.009). There were no significant differences of the remaining MR features and CNV sub-groups. MRI features, including the presence of necrosis, larger tumor size and higher rCBV, were seen more frequently in IDH-mutated gliomas with unstable genome-wide CNVs, suggesting a correlation of imaging phenotypes with genotype in these gliomas.
LSD1 Inhibition Induces Fetal Hemoglobin Expression and Provides a Novel Therapeutic Approach to Sickle Cell Disease
Authors: Sang Hyun Lee, Maxim Soloviev, Yan Zhang, Valerie Roman, Gengjie Yang, Kevin Bowman, Krista Burke, Alexander Margulis, Sybil O'Connor, Yan-ou Yang, Liangxing Wu, Richard Wynn, Timothy Burn, Dana Shuey, Sharon Diamond, Wenqing Yao, Gregory Hollis, Swamy Yeleswaram, Alan Roberts, Reid Huber, Peggy Scherle, Bruce Ruggeri
Journal: Blood (2016)
PDTM-15. PLX51107, A NOVEL BROMODOMAIN INHIBITOR, WORKS SYNERGISTICALLY WITH AURORA-A KINASE INHIBITOR MLN8327 IN TREATING MYC-AMPLIFIED MEDULLOBLASTOMA
Authors: Elizabeth Wadhwa, Jie Zhang, Ben Powell, Cassandra Van, Clay Gustafson, Theo Nicolaides
Journal: Neuro-Oncology (2017)

Group 3 medulloblastoma is a malignant childhood brain tumor with the worst prognosis among all subtypes of medulloblastoma. This subgroup has the highest frequency of MYC amplification. BRD4 is a member of the human bromodomain and extraterminal domain (BET) family of proteins and functions through binding acetylated lysines on histones, regulating expression of oncogenes including MYC. BET inhibitors (BETi) are a class of epigenetic drugs that have been shown to inhibit hematologic and solid malignancies, and several BETi are currently in clinical trials. PLX51107 is a novel selective small molecule inhibitor of BRD4 and is structurally unrelated to other BETi in publications and clinical trials. Prior studies have shown that Aurora-A Kinase inhibits cell growth in medulloblastoma through inhibition of pro-proliferative signaling pathways including MYC. Combination studies using Aurora-A Kinase inhibitors have shown that they act with other chemotherapeutic agents to lower their IC50. We used the medulloblastoma cell line MED8a to evaluate the therapeutic potential of PLX51107. While our results showed inhibition of cell viability of medulloblastoma in vitro with PLX51107 alone, due to reports of the development of resistance with BET inhibitor monotherapy, we evaluated the response of medulloblastoma cells to combination therapy with MLN8237, an Aurora-A kinase inhibitor. These findings have been reproduced in other medulloblastoma cell lines. Using the Chou-Talalay method, the combination of PLX51107 and MLN8237 worked synergistically to reduce MED8a cell viability. Induction of apoptosis was increased with combination therapy as compared to treatment with PLX51107 alone, and c-myc expression was decreased. Our study suggests that the combination of BET inhibitors and Aurora-A kinase inhibitors could be an effective strategy for MYC-amplified medulloblastoma therapy. The synergistic therapeutic effect may be attributed to the inhibition of MYC expression. This study provides rationale for further pursuing this combination of PLX51107 and MLN8237 in in vivo studies.
Vigilancia de la enfermedad invasiva sistémica causada por estreptococos del grupo A en Italia, 1994-96
Authors: B Suligoi, C Von Hunolstein, G Orefici, F Scopetti, M Pataracchia, D Greco
Journal: Eurosurveillance (1998)

A finales de mayo de 1994, tras haber recibido notificacion de un brote de estreptococos beta-hemoliticos del grupo A (EGA) en el Reino Unido (1), el Istituto Superiore di Sanita (ISS) establecio un sistema de vigilancia para la enfermedad sistemica invasiva por EGA. Esta iniciativa tambien constituyo la respuesta a una peticion formulada por la Organizacion Mundial de la Salud (OMS), en mayo de 1994, para establecer en Europa sistemas de vigilancia especificamente destinados a las infecciones por EGA (2). Los objetivos de este sistema eran la recogida de datos sobre la ocurrencia de estas infecciones en Italia, por un lado, y la identificacion de brotes, por otro.
P3.02-009 Mutation Detection in Cell-Free DNA from Patients with Lung Adenocarcinoma by Next-Generation Sequencing
Authors: H. Faisal, S. Hirano, F. Irisuna, S. Kimura, N. Morihara, T. Fukazawa, A. Arfan, Y. Horimasu, N. Hattori, N. Kohno, E. Hiyama
Journal: Journal of Thoracic Oncology (2017)
QLIF-20. SKIN CARE PRODUCTS COMPATIBLE WITH TUMOR TREATING FIELDS
Authors: Mario Lacouture, Hadas Sara Hershkovich, Roni Blat, Moshe Giladi, Ze’ev Bomzon, Eilon D Kirson, Uri Weinberg, Yoram Palti
Journal: Neuro-Oncology (2017)

Low intensity, intermediate frequency, alternating electric fields (TTFields) are approved for the treatment of patients with glioblastoma multiforme (GBM). TTFields are applied continuously using a set of four arrays placed on the skin. The main TTFields-related adverse event is mild-moderate dermatitis occurring under the arrays, which is primarily caused by long-term exposure to irritants and may be exacerbated by local hyperhidrosis and occlusion. Strategies that mitigate skin irritation may improve patients’ quality of life and compliance with TTFields. Antiperspirants, moisturizing creams, antibiotics, and skin barriers have been anecdotally reported to alleviate factors related to TTFields-related skin irritation. Nonetheless, not all aforementioned products are compatible with TTFields as some may increase electrical impedance, which may lead to increased temperatures beneath the arrays. This study investigated the effect of applying 40 commercially available skin care products on electrical impedance during TTFields application, using a rat model. In these experiments, 200 kHz TTFields were applied using ceramic disks and hydrogels identical to those used with human arrays. Changes in impedance caused by applying each product on the rat skin were measured using the Optune device and an LCR meter system. The review identified a set of skin care products from all 4 groups that do not lead to a significant change in the impedance. These results suggest that local application of TTFields-compatible skin care products could maintain normal electrical resistance of the scalp-array interface, thereby allowing optimal delivery of TTFields to the brain. These products should be prospectively investigated for their potential role in minimizing TTFields–related skin irritation.
Investigación de infecciones humanas por Salmonella enterica serotipo Java en Escocia y posible relación con aves de corral importadas
Authors: D J Brown, H Mather, L M Browning, J E Coia
Journal: Eurosurveillance (2003)

El analisis por PFGE de cepas de S. Java (veintinueve obtenidas del hombre, treinta de carne de ave) mostro dos grandes agrupaciones o clusters. Todos los aislamientos de ave importados de los Paises Bajos pertenecian al cluster A, que tambien contenia diez aislamientos humanos. De los treinta y siete aislamientos de esta agrupacion, treinta y uno tenian un patron JavX1 identico, similar al perfil X8 de un clon S. Java concreto predominante en la produccion avicola de varios paises europeos. El cluster B contenia diecinueve aislamientos humanos y dos de ave de origen desconocido. Estos resultados combinados con los datos epidemiologicos y la informacion sobre el origen de la carne de ave sugerian categoricamente que la carne de ave importada es una fuente importante de infecciones por Java en el hombre en Escocia.
EXTH-68. RECURRENT XENOGRAFT TUMORS UPREGULATE EGFR AFTER LENTIVIRAL VECTOR MEDIATED SUICIDE GENE THERAPY FOR GLIOBLASTOMA, BUT ARE RESISTANT TO COMBINATORIAL TREATMENT WITH ERLOTINIB
Authors: Jubayer Hossain, Lars Ystaas, Abdul Latif, Justin Joseph, Krishna Talasila, Sandra Ninzima, Kristoffer Riecken, Boris Fehse, Rolf Bjerkvig, Hrvoje Miletic
Journal: Neuro-Oncology (2017)

Lentiviral vector mediated herpes simplex virus thymidine kinase (HSV-Tk)/ ganciclovir (GCV) therapy is a very promising therapeutic option for the treatment of glioblastoma (GBM). Although this therapy leads to complete remission of GBM in an orthotopic PDX model, recurrent tumors are observed, which contain a fraction of surviving Tk-GFP+ cells. Here, we hypothesize that prolonged prodrug treatment could provide a significant survival benefit through killing of these remaining Tk-GFP+ cells. After intracranial implantation of a patient derived biopsy, tumor growth was monitored by MRI and when the tumors reached a measurable size, lentiviral vectors encoding Tk-GFP were injected intratumorally followed by intraperitoneal GCV administration for 3 weeks or oral Valganciclovir (ValGCV) administration for 3 months. After euthanasia, brains were fixed and paraffin embedded for immunohistochemical analysis and/or snap-frozen for RNA-sequencing. Initially, we sorted the remaining Tk-GFP+ glioma cells from recurrent tumors after GCV treatment and showed that these cells retained sensitivity to GCV in vitro. Therefore we decided to use prolonged administration (3 months) of valganciclovir (valGCV), which is similar to GCV but tailored for oral administration, and compared it to the 3-week period of GCV administration in vivo. Prolonged ValGCV therapy resulted in a significant survival advantage compared to short-term (3 weeks) GCV application. Nonetheless, the majority of animals treated with valGCV also developed recurrent tumors. These were more invasive compared to the primary tumors and showed significant upregulation of the epidermal growth factor receptor (EGFR) warranting for a combinatorial treatment of HSV-Tk/valGCV with an anti-EGFR therapy. However, the combination of suicide gene therapy with erlotinib, a widely used EGFR small molecule inhibitor, failed to provide survival benefit. Currently we are initiating RNA sequencing experiments on recurrent compared to primary tumors to unravel potential changes in glioma cells refractory to suicide gene therapy and/or erlotinib.
Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head &amp; Neck 1 (LUX-H&amp;N1).
Authors: Ezra E. W. Cohen, Lisa F. Licitra, Jérôme Fayette, Thomas Christoph Gauler, Paul M. Clement, Juan José Grau, Jose Maria Del Campo, Audrey Mailliez, Robert I. Haddad, Jan B. Vermorken, Makoto Tahara, Joel Guigay, Lionnel Geoffrois, Marco C. Merlano, Nicholas F. Dupuis, Barbara Burtness, Neil Gibson, Flavio Solca, Eva Ehrnrooth, Jean-Pascal H. Machiels
Journal: Journal of Clinical Oncology (2015)

6023 Background: In the Phase III LUX-H&N1 trial, afatinib improved PFS (median 2.6 vs 1.7 months; HR 0.80; p = 0.03) vs MTX in second-line R/M HNSCC pts. As there are no accepted predictive biomarkers in this setting, the association of pre-specified biomarkers with clinical outcomes was explored. Methods: Pts were randomized 2:1 to 40 mg/d afatinib or 40 mg/m2/wk MTX. The primary endpoint was PFS. Tumor biomarker analyses included human papillomavirus status assessed by p16 immunohistochemistry (IHC), EGFR amplification (FISH), HER3 (IHC) and PTEN (IHC) on archival tissue, and the VeriStrat proteomic signature (classifying pts likely to have good or poor outcomes with EGFR inhibitors) on plasma samples. Results: Of 483 ptsenrolled, 301 (62%) provided plasma and 234 (48%) provided tissue for biomarker analyses. A more pronounced PFS benefit with afatinib vs MTX was observed in p16-negative vs p16-positive, PTEN-high vs PTEN-low, and HER3-low vs HER3-high disease (Table). A trend towards prolonged PFS was observed with afatinib vs MTX in EGFR-amplified tumors. PFS was similar with afatinib and MTX in VeriStrat good and poor groups. Further tumor samples are being analyzed and updated results of PFS and OS will be presented. Conclusions: Subgroups of R/M HNSCC pts who may achieve increased benefit from afatinib vs MTX were preliminarily identified based on biomarkers. PFS benefit with afatinib was more pronounced in pts with p16-negative, PTEN-high, HER3-low, and EGFR-amplified disease. Clinical trial information: NCT01345682. Subgroup No. of pts (Afatinib vs MTX) Median PFS, mos (Afatinib vs MTX) HR (95% CI) (Afatinib vs MTX) p-value p16-neg p16-pos 135 vs 64 23 vs 12 2.7 vs 1.6 2.0 vs 2.3 0.70 (0.50, 0.97) 0.81 (0.39, 1.69) 0.029 0.564 EGFR-amplified EGFR not amplified 48 vs 17 47 vs 19 2.8 vs 2.2 1.6 vs 2.1 0.64 (0.34, 1.20) 1.25 (0.70, 2.23) 0.162 0.455 HER3-low HER3-high 49 vs 17 64 vs 26 2.9 vs 2.0 1.7 vs 2.4 0.47 (0.25, 0.86) 1.33 (0.79, 2.24) 0.014 0.289 PTEN-high PTEN-low 30 vs 12 82 vs 33 2.9 vs 1.4 2.6 vs 2.7 0.36 (0.16, 0.81) 1.01 (0.65, 1.58) 0.014 0.965 VeriStrat: good VeriStrat: poor 127 vs 69 70 vs 35 2.7 vs 2.0 1.5 vs 1.5 0.79 (0.57, 1.09) 0.91 (0.58, 1.43) 0.145 0.678